Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

A Novel Molecular Grading Model: Combination of Ki67 and VEGF in Predicting Tumor Recurrence and Progression in Non-invasive Urothelial Bladder Cancer

  • Chen, Jun-Xing (Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University) ;
  • Deng, Nan (Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University) ;
  • Chen, Xu (Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University) ;
  • Chen, Ling-Wu (Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University) ;
  • Qiu, Shao-Peng (Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University) ;
  • Li, Xiao-Fei (Department of Urology, the First Affiliated Hospital of Sun Yat-Sen University) ;
  • Li, Jia-Ping (Department of Interventional Oncology, the First Affiliated Hospital of Sun Yat-Sen University)
  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To assess efficacy of Ki67 combined with VEGF as a molecular grading model to predict outcomes with non-muscle invasive bladder cancer (NMIBC). Materials: 72 NMIBC patients who underwent transurethral resection (TUR) followed by routine intravesical instillations were retrospectively analyzed in this study. Univariate and multivariate analyses were performed to confirm the prognostic values of the Ki67 labeling index (LI) and VEGF scoring for tumor recurrence and progression. Results: The novel molecular grading model for NMIBC contained three molecular grades including mG1 (Ki67 $LI{\leq}25%$, VEGF $scoring{\leq}8$), mG2 (Ki67 LI>25%, VEGF $scoring{\leq}8$; or Ki67 $LI{\leq}25%$, VEGF scoring > 8), and mG3 (Ki67 LI > 25%, VEGF scoring > 8), which can indicate favorable, intermediate and poor prognosis, respectively. Conclusions: The described novel molecular grading model utilizing Ki67 LI and VEGF scoring is helpful to effectively and accurately predict outcomes and optimize personal therapy.

Keywords

References

  1. Al-Abbasi DS, Al-Janabi AA, Al-Toriahi KM, et al (2009). Expression of VEGF in urinary bladder transitional cell carcinoma in an Iraqi population subjected to depleted uranium: an immunohistochemical study. Appl Immunohistochem Mol Morphol, 17, 307-11. https://doi.org/10.1097/PAI.0b013e3181941794
  2. Bryan RT, Zeegers MP, James ND, et al (2010). Biomarkers in bladder cancer. BJU Int, 105, 608-13. https://doi.org/10.1111/j.1464-410X.2009.08880.x
  3. Chade DC, Shariat SF, Godoy G, et al (2009). Critical review of biomarkers for the early detection and surveillance of bladder cancer. J Mens Health, 6, 368-82. https://doi.org/10.1016/j.jomh.2009.07.004
  4. Cheng L, Neumann RM, Weaver AL, et al (1999). Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol, 17, 3182-7. https://doi.org/10.1200/JCO.1999.17.10.3182
  5. El-Chennawi FA, Auf FA, Metwally SS, et al (2009). Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer. World J Gastrointest Oncol, 1, 62-8. https://doi.org/10.4251/wjgo.v1.i1.62
  6. Evans CP, Debruyne F, Payne H, et al (2007). Bladder cancer: Management and future directions. Eur Urol Suppl, 6, 365-73. https://doi.org/10.1016/j.eursup.2006.12.005
  7. Fauconnet S, Bernardini S, Lascombe I, et al (2009). Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer. Oncol Rep, 21, 1495-504.
  8. Gonul II, Akyurek N, Dursun A, et al (2008). Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder. Pathol Res Pract, 204, 707-17. https://doi.org/10.1016/j.prp.2008.03.011
  9. Habuchi T, Marberger M, Droller MJ, et al (2005). Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology, 66, 64-74. https://doi.org/10.1016/j.urology.2005.08.065
  10. Hilmy M, Campbell R, Bartlett JM, et al (2006). The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX- 2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer, 95, 1234-8. https://doi.org/10.1038/sj.bjc.6603415
  11. Kilicarslan AB, Ogus M, Arici C, et al (2003). Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. Apmis, 111, 439-43. https://doi.org/10.1034/j.1600-0463.2003.t01-1-1110209.x
  12. Klein M, Vignaud JM, Hennequin V, et al (2001). Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab, 86, 656-8. https://doi.org/10.1210/jc.86.2.656
  13. Lebret T, Becette V, Herve JM, et al (2000). Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol, 37, 654-9. https://doi.org/10.1159/000020233
  14. Li R, Heydon K, Hammond ME, et al (2004). Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res, 10, 4118-24. https://doi.org/10.1158/1078-0432.CCR-1052-03
  15. Margulis V, Lotan Y, Karakiewicz PI, et al (2009), Multiinstitutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst, 101, 114-9. https://doi.org/10.1093/jnci/djn451
  16. Margulis V, Shariat SF, Ashfaq R, et al (2006). Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res, 12, 7369-73. https://doi.org/10.1158/1078-0432.CCR-06-1472
  17. M Burger SDAH (2007). Mcm2 predicts recurrence hazard in stage TaT1 bladder cancer more accurately than CK20 Ki67 and histological grade. Br J Cancer, 96, 1711-5. https://doi.org/10.1038/sj.bjc.6603784
  18. Oka N, Yamamoto Y, Takahashi M, et al (2005). Expression of angiopoietin-1 and-2, and its clinical significance in human bladder cancer. Bju Int, 95, 660-3. https://doi.org/10.1111/j.1464-410X.2005.05358.x
  19. Sakamoto S, Ryan AJ, Kyprianou N (2008). Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem, 103, 691-708. https://doi.org/10.1002/jcb.21442
  20. Santos L, Amaro T, Costa C, et al (2003). Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer, 105, 267-72. https://doi.org/10.1002/ijc.11049
  21. Shirotake S, Miyajima A, Kosaka T, et al (2011). Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. Urology, 77, e19-25. https://doi.org/10.1016/j.urology.2010.07.506
  22. van der Loos CM, Meijer-Jorna LB, Broekmans ME, et al (2009). Anti-human Vascular Endothelial Growth Factor (VEGF) Antibody Selection for Immunohistochemical Staining of Proliferating Blood Vessels. J Histochem Cytochem, 58, 109-18.
  23. van Rhijn BW, Vis AN, van der Kwast TH, et al (2003). Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol, 21, 1912-21. https://doi.org/10.1200/JCO.2003.05.073
  24. van Rhijn BW, Zuiverloon TC, Vis AN, et al (2010). Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol, 58, 433-41. https://doi.org/10.1016/j.eururo.2010.05.043
  25. Viale G, Regan MM, Mastropasqua MG, et al (2008). Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst, 100, 207-12. https://doi.org/10.1093/jnci/djm289
  26. Vidal O, Soriano-Izquierdo A, Pera M, et al (2008). Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg, 12, 1005-14. https://doi.org/10.1007/s11605-007-0336-3
  27. Wolman SR, Goldman B, Slovak ML, et al (2007). Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study. Cancer Genet Cytogenet, 176, 22-7. https://doi.org/10.1016/j.cancergencyto.2007.02.015
  28. Yurakh AO, Ramos D, Calabuig-Farinas S, et al (2006). Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol, 50, 506-15; discussion 515. https://doi.org/10.1016/j.eururo.2006.03.027

Cited by

  1. Ki67 is a promising molecular target in the diagnosis of cancer (Review) pp.1791-3004, 2015, https://doi.org/10.3892/mmr.2014.2914
  2. Joint Effect of Urinary Total Arsenic Level and VEGF-A Genetic Polymorphisms on the Recurrence of Renal Cell Carcinoma vol.10, pp.12, 2015, https://doi.org/10.1371/journal.pone.0145410
  3. Bladder cancer biomarker array to detect aberrant levels of proteins in urine vol.140, pp.3, 2015, https://doi.org/10.1039/C4AN01432D
  4. Can Recurrence and Progression be Predicted by HYAL-1 Expression in Primary T1 Bladder Cancer? vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10401
  5. Prognostic Significance of Nestin Expression in pT1 High-Grade Bladder Urothelial Carcinoma Patients Treated with Intravesical BCG vol.15, pp.24, 2014, https://doi.org/10.7314/APJCP.2014.15.24.10813
  6. Diagnostic and Therapeutic Implications of the Vascular Endothelial Growth Factor Family in Cancer vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1677
  7. New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer vol.56, pp.8, 2015, https://doi.org/10.4111/kju.2015.56.8.553
  8. Clinicopathological and Prognostic Value of Ki-67 Expression in Bladder Cancer: A Systematic Review and Meta-Analysis vol.11, pp.7, 2016, https://doi.org/10.1371/journal.pone.0158891
  9. A Novel Combination of Wheat Peptides and Fucoidan Attenuates Ethanol-Induced Gastric Mucosal Damage through Anti-Oxidant, Anti-Inflammatory, and Pro-Survival Mechanisms vol.9, pp.9, 2017, https://doi.org/10.3390/nu9090978